Letrozolo Almus

Letrozole, the active ingredient in Letrozolo Almus, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women, where it lowers estrogen production to help control tumor growth. The medication is administered once daily and is part of standard endocrine therapy protocols.

GNH USA supplies Letrozolo Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company ensures quality assurance, regulatory compliance, and reliable logistics for global healthcare partners.

Letrozole acts as an aromatase inhibitor and is indicated for conditions driven by estrogen signaling in breast cancer.

Hormone receptor‑positive breast cancer (postmenopausal): reduces tumor growth by decreasing circulating estrogen levels. Adjuvant therapy for early‑stage hormone receptor‑positive breast cancer (postmenopausal): helps prevent disease recurrence after surgery. Advanced or metastatic breast cancer (postmenopausal): delays progression when used alone or with other endocrine agents.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: transient increase in body temperature sensation. - Joint and muscle pain: arthralgia or myalgia. - Nausea: mild gastrointestinal upset. - Fatigue: reduced energy levels.

Serious or Rare Side Effects: - Severe liver injury: elevated transaminases or hepatitis. - Bone fractures: decreased bone mineral density leading to fracture risk. - Pulmonary embolism: formation of blood clots in the lungs.

When prescribing Letrozolo Almus, clinicians should observe several precautionary measures to ensure patient safety. - Liver function monitoring: assess baseline enzymes and repeat periodically. - Bone health assessment: evaluate bone mineral density and consider calcium/vitamin D supplementation. - Cardiovascular risk evaluation: screen for thromboembolic history and manage risk factors. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception in women of childbearing potential. - Drug interaction review: check concomitant medications for potential CYP interactions. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Letrozole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP2C19 inhibitors (e.g., fluconazole): may increase letrozole plasma levels. - Estrogen‑containing hormone therapy: antagonizes letrozole’s estrogen‑lowering effect. - Tamoxifen: concurrent use reduces therapeutic benefit of both agents.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): letrozole may enhance anticoagulant effect, requiring INR monitoring. - Statins: potential for altered lipid metabolism; monitor lipid profile. - CYP3A4 inducers (e.g., rifampin): may lower letrozole concentrations, reducing efficacy.